: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

As of October 2023, Amedeo had
12,263 active subscribers

Breast Cancer

Free Subscription

Articles published in BMC Cancer
Retrieve available abstracts of 406 articles:
HTML format

Single Articles

December 2023

ELIA C, de Girolamo L, Clarisse B, Galin M, et al
Effects of sleep disturbances and circadian rhythms modifications on cognition in breast cancer women before and after adjuvant chemotherapy: the ICANSLEEP-1 protocol.
BMC Cancer. 2023;23:1178.
PubMed Abstract available

YIN Y, Tong L, Wan Z, Sui Y, et al
CYP4B1 polymorphisms and the risk of breast cancer in Chinese women: a case-control study.
BMC Cancer. 2023;23:1177.
PubMed Abstract available

YU F, Li L, Zhang M, Sun S, et al
Correction: Phosphorylation of EZH2 differs HER2-positive breast cancer invasiveness in a site-specific manner.
BMC Cancer. 2023;23:1176.
PubMed

November 2023

ZHU QM, Li HX, Ma PQ, Wu LX, et al
A potential immunotherapy target for breast cancer: parenchymal and immune-stromal expression of the NLRP3 inflammasome pathway.
BMC Cancer. 2023;23:1163.
PubMed Abstract available

JACOBSEN S, Glavind-Kristensen M, Jensen AB, Forman A, et al
Vaginal CO(2) laser therapy for genitourinary syndrome in breast cancer survivors-VagLaser study protocol: a randomized blinded, placebo-controlled trial.
BMC Cancer. 2023;23:1164.
PubMed Abstract available

LI L, Zhang H, Wang L, Xie C, et al
Optimization of supraclavicular lymph node clinical target volume delineation in high-risk breast cancer: a single center experience and recommendation.
BMC Cancer. 2023;23:1168.
PubMed Abstract available

EMAD B, WalyEldeen AA, Hassan H, Sharaky M, et al
Yttrium Oxide nanoparticles induce cytotoxicity, genotoxicity, apoptosis, and ferroptosis in the human triple-negative breast cancer MDA-MB-231 cells.
BMC Cancer. 2023;23:1151.
PubMed Abstract available

JAVADI M, Sazegar H, Doosti A
Genome editing approaches with CRISPR/Cas9: the association of NOX4 expression in breast cancer patients and effectiveness evaluation of different strategies of CRISPR/Cas9 to knockout Nox4 in cancer cells.
BMC Cancer. 2023;23:1155.
PubMed Abstract available

LIU CJ, Zhang L, Sun Y, Geng L, et al
Application of CT and MRI images based on an artificial intelligence algorithm for predicting lymph node metastasis in breast cancer patients: a meta-analysis.
BMC Cancer. 2023;23:1134.
PubMed Abstract available

LUNDO K, Dmytriyeva O, Spohr L, Goncalves-Alves E, et al
Lactate receptor GPR81 drives breast cancer growth and invasiveness through regulation of ECM properties and Notch ligand DLL4.
BMC Cancer. 2023;23:1136.
PubMed Abstract available

FAUSER D, Rimalis-Vogt E, Mattes J, Bethge M, et al
Psychological interventions during breast cancer rehabilitation: a randomized controlled trial comparing structured short-term psychotherapy versus non-specific group discussion.
BMC Cancer. 2023;23:1133.
PubMed Abstract available

KLAASSEN-DEKKER A, Drossaert CHC, Van Maaren MC, Van Leeuwen-Stok AE, et al
Personalized surveillance and aftercare for non-metastasized breast cancer: the NABOR study protocol of a multiple interrupted time series design.
BMC Cancer. 2023;23:1112.
PubMed Abstract available

HE H, Wang S, Zhang W, Gao S, et al
Downregulation of TAB182 promotes cancer stem-like cell properties and therapeutic resistance in triple-negative breast cancer cells.
BMC Cancer. 2023;23:1101.
PubMed Abstract available

NAJAFI S, Ansari M, Omidi Z, Olfatbakhsh A, et al
Efficacy and safety of diphereline 11.25 mg, microrelin 11.25 mg, and microrelin 3.75 mg in premenopausal patients with breast cancer: a non-inferiority randomized clinical trial.
BMC Cancer. 2023;23:1093.
PubMed Abstract available

MA L, Yang Y, Ma J, Mao L, et al
Correlation between AI-based CT organ features and normal lung dose in adjuvant radiotherapy following breast-conserving surgery: a multicenter prospective study.
BMC Cancer. 2023;23:1085.
PubMed Abstract available

DROUYER A, Beaussire L, Jorda P, Leheurteur M, et al
Clinical relevance of circulating ESR1 mutations during endocrine therapy for advanced hormone-dependent endometrial carcinoma.
BMC Cancer. 2023;23:1061.
PubMed Abstract available

EL-GAMAL R, Elfarrash S, El-Nablaway M, Salem AA, et al
Anti-proliferative activity of RIHMS-Qi-23 against MCF-7 breast cancer cell line is through inhibition of cell proliferation and senescence but not inhibition of targeted kinases.
BMC Cancer. 2023;23:1053.
PubMed Abstract available

FENTIE H, Ntenda PAM, Tiruneh FN
Dietary pattern and other factors of breast cancer among women: a case control study in Northwest Ethiopia.
BMC Cancer. 2023;23:1050.
PubMed Abstract available

October 2023

FELDMAN D, Sinberger LA, Salmon-Divon M, Ben-Dror J, et al
Impact of the OncotypeDX score and HER2 RNA PCR levels on HER2-low IHC levels in primary and metastasized tumors.
BMC Cancer. 2023;23:1031.
PubMed Abstract available

LI Y, Han D, Shen C, Duan X, et al
Construction of a comprehensive predictive model for axillary lymph node metastasis in breast cancer: a retrospective study.
BMC Cancer. 2023;23:1028.
PubMed Abstract available

KOTEPUI K, Kotepui M, Majima HJ, Tangpong J, et al
Association between NDRG1 protein expression and aggressive features of breast cancer: a systematic review and meta-analysis.
BMC Cancer. 2023;23:1003.
PubMed Abstract available

NAGASAKA M, Zhang SS, Baca Y, Xiu J, et al
Pan-tumor survey of ROS1 fusions detected by next-generation RNA and whole transcriptome sequencing.
BMC Cancer. 2023;23:1000.
PubMed Abstract available

CHEN D, Wang Q, Dong M, Chen F, et al
Analysis of neoadjuvant chemotherapy for breast cancer: a 20-year retrospective analysis of patients of a single institution.
BMC Cancer. 2023;23:984.
PubMed Abstract available

TUGRAL A, Aribas Z, Akyol M, Bakar Y, et al
Assessment of sensorimotor and strength related function of breast cancer patients during systemic drug therapy: a prospective observational study.
BMC Cancer. 2023;23:981.
PubMed Abstract available

WANG Z, Ren H, Zhu G, Zhang L, et al
High expression of CCDC69 is correlated with immunotherapy response and protective effects on breast cancer.
BMC Cancer. 2023;23:974.
PubMed Abstract available

YAN H, Ren W, Jia M, Xue P, et al
Breast cancer risk factors and mammographic density among 12518 average-risk women in rural China.
BMC Cancer. 2023;23:952.
PubMed Abstract available

YU F, Li L, Zhang M, Sun S, et al
Phosphorylation of EZH2 differs HER2-positive breast cancer invasiveness in a site-specific manner.
BMC Cancer. 2023;23:948.
PubMed Abstract available

ANDREW TONG JW, Hee MQ
The impact of an online educational game on breast cancer awareness among university female students, Malaysia: a pilot study.
BMC Cancer. 2023;23:947.
PubMed Abstract available

JAHROMI MK, Tehrani AN, Farhadnejad H, Emamat H, et al
Dietary advanced glycation end products are associated with an increased risk of breast cancer in Iranian adults.
BMC Cancer. 2023;23:932.
PubMed Abstract available

WANG J, Huang J, Ding H, Ma J, et al
Functional analysis of tumor-derived immunoglobulin lambda and its interacting proteins in cervical cancer.
BMC Cancer. 2023;23:929.
PubMed Abstract available

September 2023

YANG X, Li Y, Lu X, Ren X, et al
Clinicopathological features and prognosis of patients with HER2-low breast cancer.
BMC Cancer. 2023;23:914.
PubMed Abstract available

FANG T, Zhang Z, Zhou H, Wu W, et al
Effect of genetic liability to migraine and its subtypes on breast cancer: a mendelian randomization study.
BMC Cancer. 2023;23:887.
PubMed Abstract available

DIVOUX J, Florent R, Jacobs M, Lequesne J, et al
The TRIPLEX study: use of patient-derived tumor organoids as an innovative tool for precision medicine in triple-negative breast cancer.
BMC Cancer. 2023;23:883.
PubMed Abstract available

SAWHNEY R, Nathani P, Patil P, Bhandarkar P, et al
Recognising socio-cultural barriers while seeking early detection services for breast cancer: a study from a Universal Health Coverage setting in India.
BMC Cancer. 2023;23:881.
PubMed Abstract available

MYERS C, Waldron C, Bennett K, Cahir C, et al
Impact of the COVID-19 pandemic on women living with and beyond breast cancer: a qualitative study of women's experiences and how they varied by social determinants of health.
BMC Cancer. 2023;23:867.
PubMed Abstract available

JIANG K, Zhou D, Xu F, Xia W, et al
Genetic analysis of oligo-recurrence breast cancer: correlation with clinical outcomes.
BMC Cancer. 2023;23:869.
PubMed Abstract available

KUO SH, Tseng LM, Chen ST, Sagara Y, et al
Radiotherapy versus low-dose tamoxifen following breast-conserving surgery for low-risk and estrogen receptor-positive breast ductal carcinoma in situ: an international open-label randomized non-inferiority trial (TBCC-ARO DCIS Trial).
BMC Cancer. 2023;23:865.
PubMed Abstract available

JOSHY G, Khalatbari-Soltani S, Soga K, Butow P, et al
Pain and its interference with daily living in relation to cancer: a comparative population-based study of 16,053 cancer survivors and 106,345 people without cancer.
BMC Cancer. 2023;23:774.
PubMed Abstract available

HEINZE F, Czwikla J, Heinig M, Langner I, et al
German mammography screening program: program sensitivity between 2010 and 2016 estimated based on German health claims data.
BMC Cancer. 2023;23:852.
PubMed Abstract available

GUI Z, Tian Y, Yu T, Liu S, et al
Clinical implications and immune features of CENPN in breast cancer.
BMC Cancer. 2023;23:851.
PubMed Abstract available

ZHU M, Li X, Feng Y, Jia T, et al
Impact of CD40 gene polymorphisms on the risk of cervical squamous cell carcinoma: a case-control study.
BMC Cancer. 2023;23:845.
PubMed Abstract available

CHEN HL, Huang FB, Chen Q, Deng YC, et al
Impact of estrogen receptor expression level on response to neoadjuvant chemotherapy and prognosis in HER2-negative breast cancers.
BMC Cancer. 2023;23:841.
PubMed Abstract available

RYU S, Yoon SH, Song J, Choi Y, et al
Impact of media compositions and culture systems on the immunophenotypes of patient-derived breast cancer cells.
BMC Cancer. 2023;23:831.
PubMed Abstract available

August 2023

LIU Y, Wu J, Ji Z, Chen L, et al
Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/HER-2 - metastatic or advanced breast cancer patients: a network meta-analysis.
BMC Cancer. 2023;23:816.
PubMed Abstract available

LI Y, Wu X, Yan Y, Zhou P, et al
Automated breast volume scanner based Radiomics for non-invasively prediction of lymphovascular invasion status in breast cancer.
BMC Cancer. 2023;23:813.
PubMed Abstract available

JI D, Luo Y, Wang J, Chen S, et al
CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis.
BMC Cancer. 2023;23:805.
PubMed Abstract available

FENG Z, Yang X, Tian M, Zeng N, et al
BRCA genes as candidates for colorectal cancer genetic testing panel: systematic review and meta-analysis.
BMC Cancer. 2023;23:807.
PubMed Abstract available

LIU N, Kang Y, Qu N, Kong C, et al
Clinical perspectives and outcomes of the giant breast phyllodes tumor and sarcoma: a real-world retrospective study.
BMC Cancer. 2023;23:801.
PubMed Abstract available

CORTES J, Haiderali A, Huang M, Pan W, et al
Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis.
BMC Cancer. 2023;23:792.
PubMed Abstract available

KJELDSTED E, Ammitzboll G, Jorgensen LB, Lodin A, et al
Neo-train: study protocol and feasibility results for a two-arm randomized controlled trial investigating the effect of supervised exercise during neoadjuvant chemotherapy on tumour response in patients with breast cancer.
BMC Cancer. 2023;23:777.
PubMed Abstract available

WU Q, Tao X, Luo Y, Zheng S, et al
A novel super-enhancer-related gene signature predicts prognosis and immune microenvironment for breast cancer.
BMC Cancer. 2023;23:776.
PubMed Abstract available

BARTHOLOMEW K, Ghafel M, Tin Tin S, Aye PS, et al
Receipt of mastectomy and adjuvant radiotherapy following breast conserving surgery (BCS) in New Zealand women with BCS-eligible breast cancer, 2010-2015: an observational study focusing on ethnic differences.
BMC Cancer. 2023;23:766.
PubMed Abstract available

ZHOU M, Gan XL, Ren YX, Chen QX, et al
AGR2 and FOXA1 as prognostic markers in ER-positive breast cancer.
BMC Cancer. 2023;23:743.
PubMed Abstract available

OFVERHOLM A, Torngren T, Rosen A, Arver B, et al
Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer.
BMC Cancer. 2023;23:738.
PubMed Abstract available

GERNIER F, Grellard JM, Dupont C, Castel H, et al
Impact of web application support versus standard management on adherence with adjuvant hormone therapy in patients treated for breast cancer: the WEBAPPAC study.
BMC Cancer. 2023;23:736.
PubMed Abstract available

July 2023

PARIKH P, Babu G, Singh R, Krishna V, et al
Consensus guidelines for the management of HR-positive HER2/neu negative early breast cancer in India, SAARC region and other LMIC by DELPHI survey method.
BMC Cancer. 2023;23:714.
PubMed Abstract available

AFSHAR-BAKSHLOO M, Albers S, Richter C, Berninger O, et al
How breast cancer therapies impact body image - real-world data from a prospective cohort study collecting patient-reported outcomes.
BMC Cancer. 2023;23:705.
PubMed Abstract available

MITCHELL H, Mclean J, Gavin AT, Visser O, et al
Impact of COVID-19 control on lung, breast, and colorectal pathological cancer diagnoses. A comparison between the Netherlands, Aotearoa New Zealand, and Northern Ireland.
BMC Cancer. 2023;23:700.
PubMed Abstract available

JIANG Y, Zhang J, Zhong J, Liao H, et al
Efficacy and safety of PEG-rhG-CSF versus rhG-CSF in preventing chemotherapy-induced-neutropenia in early-stage breast cancer patients.
BMC Cancer. 2023;23:702.
PubMed Abstract available

CHITRANGI S, Vaity P, Jamdar A, Bhatt S, et al
Patient-derived organoids for precision oncology: a platform to facilitate clinical decision making.
BMC Cancer. 2023;23:689.
PubMed Abstract available

MERTENS E, Barrenechea-Pulache A, Sagastume D, Vasquez MS, et al
Understanding the contribution of lifestyle in breast cancer risk prediction: a systematic review of models applicable to Europe.
BMC Cancer. 2023;23:687.
PubMed Abstract available

VEYSSIERE H, Dressaire M, Pete R, Pinard C, et al
RFID trial: localization of non-palpable breast lesions using radiofrequency identification tags or wire.
BMC Cancer. 2023;23:679.
PubMed Abstract available

YANG X, Xu Y, Fu J, Shen Z, et al
Nanoparticle delivery of TFOs is a novel targeted therapy for HER2 amplified breast cancer.
BMC Cancer. 2023;23:680.
PubMed Abstract available

ZEELST LJV, Ten Wolde B, Plate JDJ, Volders JH, et al
The QUILT study: quilting sutures in patients undergoing breast cancer surgery: a stepped wedge cluster randomized trial study.
BMC Cancer. 2023;23:667.
PubMed Abstract available

LAMMINMAKI M, Leivonen A, Heinavaara S, Nygard M, et al
A population-based cohort study on changes in breast, lung and colorectal cancer incidence and mortality among non-Western immigrant women.
BMC Cancer. 2023;23:665.
PubMed Abstract available

MCNAMEE N, Catalano M, Mukhopadhya A, O'Driscoll L, et al
An extensive study of potential inhibitors of extracellular vesicles release in triple-negative breast cancer.
BMC Cancer. 2023;23:654.
PubMed Abstract available

CAI M, Li M, Lv H, Zhou S, et al
HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases.
BMC Cancer. 2023;23:656.
PubMed Abstract available

MAO X, Omeogu C, Karanth S, Joshi A, et al
Association of reproductive risk factors and breast cancer molecular subtypes: a systematic review and meta-analysis.
BMC Cancer. 2023;23:644.
PubMed Abstract available

CARRACA EV, Rodrigues B, Franco S, Nobre I, et al
Promoting physical activity through supervised vs motivational behavior change interventions in breast cancer survivors on aromatase inhibitors (PAC-WOMAN): protocol for a 3-arm pragmatic randomized controlled trial.
BMC Cancer. 2023;23:632.
PubMed Abstract available

GUNTHER M, Hentschel L, Schuler M, Muller T, et al
Developing tumor-specific PRO-CTCAE item sets: analysis of a cross-sectional survey in three German outpatient cancer centers.
BMC Cancer. 2023;23:629.
PubMed Abstract available

ELIASSEN FM, Blafjelldal V, Helland T, Hjorth CF, et al
Importance of endocrine treatment adherence and persistence in breast cancer survivorship: a systematic review.
BMC Cancer. 2023;23:625.
PubMed Abstract available

SHI Y, Qiu Z, Yu J, Li Z, et al
Association between insulin resistance and cardiac remodeling in HER2-positive breast cancer patients: a real-world study.
BMC Cancer. 2023;23:615.
PubMed Abstract available

June 2023

FOLDI J, Tsagianni A, Salganik M, Schnabel CA, et al
Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer.
BMC Cancer. 2023;23:606.
PubMed Abstract available

HALLSSON LR, Sroczynski G, Engel J, Siebert U, et al
Decision-analytic evaluation of the comparative effectiveness and cost-effectiveness of strategies to prevent breast and ovarian cancer in German women with BRCA-1/2 mutations.
BMC Cancer. 2023;23:590.
PubMed Abstract available

FAN R, Wang L, Bu X, Wang W, et al
Unmet supportive care needs of breast cancer survivors: a systematic scoping review.
BMC Cancer. 2023;23:587.
PubMed Abstract available

HUANG Q, Mo J, Yang H, Ji Y, et al
Analysis of m7G-Related signatures in the tumour immune microenvironment and identification of clinical prognostic regulators in breast cancer.
BMC Cancer. 2023;23:583.
PubMed Abstract available

RYU JM, Lee J, Lee J, Ko B, et al
Mastectomy with Reconstruction Including Robotic Endoscopic Surgery (MARRES): a prospective cohort study of the Korea Robot-Endoscopy Minimal Access Breast Surgery Study Group (KoREa-BSG) and Korean Breast Cancer Study Group (KBCSG).
BMC Cancer. 2023;23:571.
PubMed Abstract available

KANG YJ, Yoon CI, Yang YJ, Baek JM, et al
A randomized controlled trial using surgical gloves to prevent chemotherapy-induced peripheral neuropathy by paclitaxel in breast cancer patients (AIUR trial).
BMC Cancer. 2023;23:570.
PubMed Abstract available

CHRISTAKOUDI S, Tsilidis KK, Dossus L, Rinaldi S, et al
A body shape index (ABSI) is associated inversely with post-menopausal progesterone-receptor-negative breast cancer risk in a large European cohort.
BMC Cancer. 2023;23:562.
PubMed Abstract available

XIE Y, Hu T, Chen R, Chang H, et al
Predicting acute radiation dermatitis in breast cancer: a prospective cohort study.
BMC Cancer. 2023;23:537.
PubMed Abstract available

COUTURAUD F, Mahe I, Schmidt J, Gleize JC, et al
Adult breast, lung, pancreatic, upper and lower gastrointestinal cancer patients with hospitalized venous thromboembolism in the national French hospital discharge database.
BMC Cancer. 2023;23:531.
PubMed Abstract available

CHEN J, Li Z, Han Z, Kang D, et al
Prognostic value of tumor necrosis based on the evaluation of frequency in invasive breast cancer.
BMC Cancer. 2023;23:530.
PubMed Abstract available

HUO Q, Wang J, Xie N
High HSPB1 expression predicts poor clinical outcomes and correlates with breast cancer metastasis.
BMC Cancer. 2023;23:501.
PubMed Abstract available

CORCORAN L, Friedenreich CM, McNeely ML, Culos-Reed NS, et al
A qualitative study examining newly diagnosed breast cancer patients' experiences of participating in the Alberta Moving Beyond Breast Cancer (AMBER) prospective cohort study.
BMC Cancer. 2023;23:500.
PubMed Abstract available

PASCETTA SA, Kirsh SM, Cameron M, Uniacke J, et al
Pharmacological inhibition of neuropeptide Y receptors Y1 and Y5 reduces hypoxic breast cancer migration, proliferation, and signaling.
BMC Cancer. 2023;23:494.
PubMed Abstract available

POURNABEE M, Keshavarz-Fathi M, Esmaeili P, Mahdavi Sharif P, et al
Characterization of immune checkpoints expression and lymphocyte densities of iranian breast cancer patients; the co-expression status and clinicopathological associates.
BMC Cancer. 2023;23:495.
PubMed Abstract available

May 2023

LIN Y, Zhao Y, Chen M, Li Z, et al
CYD0281, a Bcl-2 BH4 domain antagonist, inhibits tumor angiogenesis and breast cancer tumor growth.
BMC Cancer. 2023;23:479.
PubMed Abstract available

LI G, Sun Y, Huang Y, Lian J, et al
Fusobacterium nucleatum-derived small extracellular vesicles facilitate tumor growth and metastasis via TLR4 in breast cancer.
BMC Cancer. 2023;23:473.
PubMed Abstract available

AKANDA MR, Ahn EJ, Kim YJ, Salam SMA, et al
Analysis of stromal PDGFR-beta and alpha-SMA expression and their clinical relevance in brain metastases of breast cancer patients.
BMC Cancer. 2023;23:468.
PubMed Abstract available

SHARMA N, Ng AY, James JJ, Khara G, et al
Multi-vendor evaluation of artificial intelligence as an independent reader for double reading in breast cancer screening on 275,900 mammograms.
BMC Cancer. 2023;23:460.
PubMed Abstract available

CAO M, Lu H, Yan S, Pang H, et al
Apatinib plus etoposide in pretreated patients with advanced triple-negative breast cancer: a phase II trial.
BMC Cancer. 2023;23:463.
PubMed Abstract available

TAKANO EA, Younes MM, Meehan K, Spalding L, et al
Estrogen receptor beta expression in triple negative breast cancers is not associated with recurrence or survival.
BMC Cancer. 2023;23:459.
PubMed Abstract available

DROZD C, Curtit E, Jacquinot Q, Marquine C, et al
A randomized trial to evaluate the effects of a supervised exercise program on insomnia in patients with non-metastatic breast cancer undergoing chemotherapy: design of the FATSOMCAN study.
BMC Cancer. 2023;23:449.
PubMed Abstract available

YAO L, Li Y, Li S, Wang M, et al
ARHGAP39 is a prognostic biomarker involved in immune infiltration in breast cancer.
BMC Cancer. 2023;23:440.
PubMed Abstract available

YAMADA Y, Simon R, Iwane K, Nakanishi Y, et al
An exploratory study for tuft cells in the breast and their relevance in triple-negative breast cancer: the possible relationship of SOX9.
BMC Cancer. 2023;23:438.
PubMed Abstract available

ZHANG J, Wu Q, Yin W, Yang L, et al
Development and validation of a radiopathomic model for predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer patients.
BMC Cancer. 2023;23:431.
PubMed Abstract available

PAKIET A, Jedrzejewska A, Duzowska K, Waclawska A, et al
Serum fatty acid profiles in breast cancer patients following treatment.
BMC Cancer. 2023;23:433.
PubMed Abstract available

CIVIL YA, Oei AL, Duvivier KM, Bijker N, et al
Prediction of pathologic complete response after single-dose MR-guided partial breast irradiation in low-risk breast cancer patients: the ABLATIVE-2 trial-a study protocol.
BMC Cancer. 2023;23:419.
PubMed Abstract available

ZHAO C, Zeng N, Zhou X, Tan Y, et al
CAA-derived IL-6 induced M2 macrophage polarization by activating STAT3.
BMC Cancer. 2023;23:392.
PubMed Abstract available

April 2023

HAYAMA S, Nakamura R, Ishige T, Sangai T, et al
The impact of PIK3CA mutations and PTEN expression on the effect of neoadjuvant therapy for postmenopausal luminal breast cancer patients.
BMC Cancer. 2023;23:384.
PubMed Abstract available

DAI X, Cai L, Zhang Z, Li J, et al
SNRPD1 conveys prognostic value on breast cancer survival and is required for anthracycline sensitivity.
BMC Cancer. 2023;23:376.
PubMed Abstract available

ZHANG W, Lin S, Zeng B, Chen X, et al
High leukocyte mitochondrial DNA copy number contributes to poor prognosis in breast cancer patients.
BMC Cancer. 2023;23:377.
PubMed Abstract available

AN Y, Fnu G, Xie C, Weber GF, et al
Meta-analysis of Osteopontin splice variants in cancer.
BMC Cancer. 2023;23:373.
PubMed Abstract available

POMEY MP, Nelea MI, Normandin L, Vialaron C, et al
An exploratory cross-sectional study of the effects of ongoing relationships with accompanying patients on cancer care experience, self-efficacy, and psychological distress.
BMC Cancer. 2023;23:369.
PubMed Abstract available

BASSI N, Hovland HN, Rasheed K, Jarhelle E, et al
Functional analyses of rare germline BRCA1 variants by transcriptional activation and homologous recombination repair assays.
BMC Cancer. 2023;23:368.
PubMed Abstract available

LIU X, Sun K, Yang H, Xia L, et al
Risk factors for the development of severe breast cancer-related lymphedema: a retrospective cohort study.
BMC Cancer. 2023;23:361.
PubMed Abstract available

LI J
Chidamide enhances cytotoxicity of doxorubicin by promoting autophagy and apoptosis in breast cancer.
BMC Cancer. 2023;23:353.
PubMed Abstract available

BENZON B, Marijan S, Pervan M, Cikes Culic V, et al
Eta polycaprolactone (epsilon-PCL) implants appear to cause a partial differentiation of breast cancer lung metastasis in a murine model.
BMC Cancer. 2023;23:343.
PubMed Abstract available

MELKI R, Melloul M, Aissaoui S, El Harroudi T, et al
Increased prevalence of the founder BRCA1 c.5309G>T and recurrent BRCA2 c.1310_1313delAAGA mutations in breast cancer families from Northerstern region of Morocco: evidence of geographical specificity and high relevance for genetic counseling.
BMC Cancer. 2023;23:339.
PubMed Abstract available

CHEN Y, Xie Y, Li B, Shao H, et al
Automated Breast Ultrasound (ABUS)-based radiomics nomogram: an individualized tool for predicting axillary lymph node tumor burden in patients with early breast cancer.
BMC Cancer. 2023;23:340.
PubMed Abstract available

MA SJ, Gill J, Yendamuri K, Chatterjee U, et al
Association of progesterone receptor status with 21-gene recurrence score and survival among patients with estrogen receptor-positive breast cancer.
BMC Cancer. 2023;23:330.
PubMed Abstract available

PRIEUR A, Harper A, Khan M, Vire B, et al
Plasma hPG(80) (Circulating Progastrin) as a Novel Prognostic Biomarker for early-stage breast cancer in a breast cancer cohort.
BMC Cancer. 2023;23:305.
PubMed Abstract available

LIU S, Ye Z, Xue VW, Sun Q, et al
KIF2C is a prognostic biomarker associated with immune cell infiltration in breast cancer.
BMC Cancer. 2023;23:307.
PubMed Abstract available

FAN L, Sui XY, Jin X, Zhang WJ, et al
High expression of TLR3 in triple-negative breast cancer predicts better prognosis-data from the Fudan University Shanghai Cancer Center cohort and tissue microarrays.
BMC Cancer. 2023;23:298.
PubMed Abstract available

March 2023

SONG C, Shang F, Tu W, Liu X, et al
Integrated pancancer analysis reveals the oncogene characteristics and prognostic value of DIP2B in breast cancer.
BMC Cancer. 2023;23:296.
PubMed Abstract available

BARUA D, Sultana A, Islam MN, Cox F, et al
RRM2 and CDC6 are novel effectors of XBP1-mediated endocrine resistance and predictive markers of tamoxifen sensitivity.
BMC Cancer. 2023;23:288.
PubMed Abstract available

DEUTSCHMANN C, Singer CF, Gschwantler-Kaulich D, Pfeiler G, et al
Residual fibroglandular breast tissue after mastectomy is associated with an increased risk of a local recurrence or a new primary breast cancer".
BMC Cancer. 2023;23:281.
PubMed Abstract available

JIAN FX, Bao PX, Li WF, Cui YH, et al
Negative regulation of CD44st by miR-138-5p affects the invasive ability of breast cancer cells and patient prognosis after breast cancer surgery.
BMC Cancer. 2023;23:269.
PubMed Abstract available

WANG Y, Du L, Jing J, Zhao X, et al
Leptin and leptin receptor expression as biomarkers for breast cancer: a retrospective study.
BMC Cancer. 2023;23:260.
PubMed Abstract available

LIU E, Zhang F, Xu T, Ye L, et al
Relationship between tumor microbiota transcriptional activity and gene expression in breast cancer.
BMC Cancer. 2023;23:252.
PubMed Abstract available

ZHANG C, Qi L, Cai J, Wu H, et al
Clinicomics-guided distant metastasis prediction in breast cancer via artificial intelligence.
BMC Cancer. 2023;23:239.
PubMed Abstract available

MA R, Wei W, Ye H, Dang C, et al
A nomogram based on platelet-to-lymphocyte ratio for predicting pathological complete response of breast cancer after neoadjuvant chemotherapy.
BMC Cancer. 2023;23:245.
PubMed Abstract available

TAKADA K, Kashiwagi S, Iimori N, Kouhashi R, et al
Impact of oral statin therapy on clinical outcomes in patients with cT1 breast cancer.
BMC Cancer. 2023;23:224.
PubMed Abstract available

SANDAMALI JAN, Hewawasam RP, Fernando MACSS, Jayatilaka KAPW, et al
Electrocardiographic and biochemical analysis of anthracycline induced cardiotoxicity in breast cancer patients from Southern Sri Lanka.
BMC Cancer. 2023;23:210.
PubMed Abstract available

MA Y, Lv M, Yuan P, Chen X, et al
Dyslipidemia is associated with a poor prognosis of breast cancer in patients receiving neoadjuvant chemotherapy.
BMC Cancer. 2023;23:208.
PubMed Abstract available

RYU J, Lee EY, Min J, Yeon S, et al
Effect of a 1-year tailored exercise program according to cancer trajectories in patients with breast cancer: study protocol for a randomized controlled trial.
BMC Cancer. 2023;23:200.
PubMed Abstract available

February 2023

KARACIN C, Oksuzoglu B, Demirci A, Keskinkilic M, et al
Correction: Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy.
BMC Cancer. 2023;23:192.
PubMed

LUO J, Kibriya MG, Chen H, Kim K, et al
A metabolome-wide case-control study of african american breast cancer patients.
BMC Cancer. 2023;23:183.
PubMed Abstract available

SHI Q, Yu J, Liu D, Ren F, et al
Distribution, dynamic evolution, and clinical outcomes of patients with advanced breast cancer according to HER2 expression.
BMC Cancer. 2023;23:173.
PubMed Abstract available

RASHA F, Boligala GP, Yang MV, Martinez-Marin D, et al
Dishevelled 2 regulates cancer cell proliferation and T cell mediated immunity in HER2-positive breast cancer.
BMC Cancer. 2023;23:172.
PubMed Abstract available

RASHED A, Fitzpatrick OM, Easty DJ, Coyne Z, et al
An observational study of dose dense chemotherapy with lipegfilgrastim support in early breast cancer.
BMC Cancer. 2023;23:171.
PubMed Abstract available

AL-KEILANI MS, Bdeir R, Elstaty RI, Alqudah MA, et al
Expression of substance P, neurokinin 1 receptor, Ki-67 and pyruvate kinase M2 in hormone receptor negative breast cancer and evaluation of impact on overall survival.
BMC Cancer. 2023;23:158.
PubMed Abstract available

VOLKEL V, Steinger B, Koller M, Klinkhammer-Schalke M, et al
Colorectal cancer survivors' long-term recollections of their illness and therapy up to seven years after enrolment into a randomised controlled clinical trial.
BMC Cancer. 2023;23:149.
PubMed Abstract available

KARACIN C, Oksuzoglu B, Demirci A, Keskinkilic M, et al
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy.
BMC Cancer. 2023;23:136.
PubMed Abstract available

GHEYBI E, Asoodeh A, Amani J
Preparation of chitosan nanoparticle containing recombinant CD44v antigen and evaluation of its immunization capacity against breast cancer in BALB/c mice.
BMC Cancer. 2023;23:134.
PubMed Abstract available

CHEN X, Zhang J, Lei X, Yang L, et al
CD1C is associated with breast cancer prognosis and immune infiltrates.
BMC Cancer. 2023;23:129.
PubMed Abstract available

AFAYA A, Laari TT, Seidu AA, Afaya RA, et al
Factors associated with the uptake of clinical breast examination among women of reproductive age in Lesotho: analysis of a national survey.
BMC Cancer. 2023;23:114.
PubMed Abstract available

January 2023

PIVOT X, Manikhas AG, Shamrai V, Dzagnidze G, et al
Final analysis of the phase 3 randomized clinical trial comparing HD201 vs. referent trastuzumab in patients with ERBB2-positive breast cancer treated in the neoadjuvant setting.
BMC Cancer. 2023;23:112.
PubMed Abstract available

YANG J, Zhao B, Ling X, Li D, et al
Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China.
BMC Cancer. 2023;23:103.
PubMed Abstract available

SHAO Z, Yu J, Cheng Y, Ma W, et al
MR imaging phenotypes and features associated with pathogenic mutation to predict recurrence or metastasis in breast cancer.
BMC Cancer. 2023;23:97.
PubMed Abstract available

JIA Z, Dai M, Shang Y, Li Y, et al
Exploring the relationships between hormone receptor, HER2 status, and bone involvement in the first distant metastases of in Chinese breast cancer patients who lacked HER2 targeted therapy.
BMC Cancer. 2023;23:93.
PubMed Abstract available

ZHOU S, Lv H, Li A, Li M, et al
A clinicopathological study and survival analysis of 99 breast cancers with HER2/CEP17 ratio >/= 2.0 and an average HER2 copy number < 4.0 per cell in China.
BMC Cancer. 2023;23:84.
PubMed Abstract available

LIEDE A, Sebby W, Miriyala AKR, Potluri R, et al
Risk of seizures in a population of women with BRCA-positive metastatic breast cancer from an electronic health record database in the United States.
BMC Cancer. 2023;23:78.
PubMed Abstract available

TAN Z, Zou Y, Zhu M, Luo Z, et al
Correction: Carnitine palmitoyl transferase 1 A is a novel diagnostic and predictive biomarker for breast cancer.
BMC Cancer. 2023;23:40.
PubMed

ZHANG C, Liang Z, Liu W, Zeng X, et al
Comparison of whole-body 18F-FDG PET/CT and PET/MRI for distant metastases in patients with malignant tumors: a meta-analysis.
BMC Cancer. 2023;23:37.
PubMed Abstract available

VERBEEK JGE, de Jong VMT, Wijnja HM, Jager A, et al
High-dose chemotherapy with stem cell rescue to treat stage III homologous deficient breast cancer: factors influencing clinical implementation.
BMC Cancer. 2023;23:26.
PubMed Abstract available

DENG H, Wang L, Wang N, Zhang K, et al
Neoadjuvant checkpoint blockade in combination with Chemotherapy in patients with tripe-negative breast cancer: exploratory analysis of real-world, multicenter data.
BMC Cancer. 2023;23:29.
PubMed Abstract available

HUANG S, Yang Q, Zheng X, Chow KM, et al
Predictors of surgery choices in women with early-stage breast cancer in China: a retrospective study.
BMC Cancer. 2023;23:23.
PubMed Abstract available

LIU S, Du S, Gao S, Teng Y, et al
A delta-radiomic lymph node model using dynamic contrast enhanced MRI for the early prediction of axillary response after neoadjuvant chemotherapy in breast cancer patients.
BMC Cancer. 2023;23:15.
PubMed Abstract available

NAFISSI N, Meshkati Yazd SM, Shahriarirad R, Zangeneh S, et al
Postoperative cosmetic outcome of intraoperative radiotherapy in comparison to whole breast radiotherapy in early stage breast cancer; a retrospective cohort study.
BMC Cancer. 2023;23:9.
PubMed Abstract available

December 2022

ZIMBALIST AS, Caan BJ, Chen WY, Mittendorf EA, et al
Metabolic abnormalities and survival among patients with non-metastatic breast cancer.
BMC Cancer. 2022;22:1361.
PubMed Abstract available

YANG H, Xu L, Guan S, Hao X, et al
Neoadjuvant docetaxel and capecitabine (TX) versus docetaxel and epirubicin (TE) for locally advanced or early her2-negative breast cancer: an open-label, randomized, multi-center, phase II Trial.
BMC Cancer. 2022;22:1357.
PubMed Abstract available

QI WX, Cao L, Zheng S, Xu C, et al
IMNI PRECISION trial protocol: a phase II, open-label, non-inferior randomized controlled trial of tailoring omission of internal mammary node irradiation for early-stage breast cancer.
BMC Cancer. 2022;22:1356.
PubMed Abstract available

BEATTY L, Kemp E, Butow P, Girgis A, et al
Finding My Way-Advanced: can a web-based psychosocial intervention improve the mental quality of life for women with metastatic breast cancer vs attention-control? Study protocol of a randomised controlled trial.
BMC Cancer. 2022;22:1353.
PubMed Abstract available

ALLAHYARI A, Ehsanpour A, Najafi B, Ansarinejad N, et al
Correction: Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial.
BMC Cancer. 2022;22:1348.
PubMed

MAHTANI R, Niyazov A, Arondekar B, Lewis K, et al
Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2-negative advanced breast cancer from th
BMC Cancer. 2022;22:1343.
PubMed Abstract available

YAO H, Li N, Yuan H
Clinical characteristics and survival analysis of Chinese ovarian cancer patients with RAD51D germline mutations.
BMC Cancer. 2022;22:1337.
PubMed Abstract available

KLAESTAD E, Opdahl S, Raj SX, Bofin AM, et al
Long term trends of breast cancer incidence according to proliferation status.
BMC Cancer. 2022;22:1340.
PubMed Abstract available

ZHANG GY, Zhang R, Bai P, Li SM, et al
Concurrent definitive chemoradiation incorporating intensity-modulated radiotherapy followed by adjuvant chemotherapy in high risk locally advanced cervical squamous cancer: a phase II study.
BMC Cancer. 2022;22:1331.
PubMed Abstract available

GENG SK, Fu SM, Zhang HW, Fu YP, et al
Predictive nomogram based on serum tumor markers and clinicopathological features for stratifying lymph node metastasis in breast cancer.
BMC Cancer. 2022;22:1328.
PubMed Abstract available

BRUAND M, Salleron J, Guihard S, Crety CM, et al
Acute skin toxicity of conventional fractionated versus hypofractionated radiotherapy in breast cancer patients receiving regional node irradiation: the real-life prospective multicenter HYPOBREAST cohort.
BMC Cancer. 2022;22:1318.
PubMed Abstract available

SIRAIT LMF, Hamajima N, Suzuki Y, Wahyuningsih ES, et al
Factors associated with positive cancer screening for the uterine cervix and breast in Jakarta Province, Indonesia: a cross-sectional study.
BMC Cancer. 2022;22:1309.
PubMed Abstract available

TERASHIMA T, Konishi H, Sato Y, Igarashi M, et al
Impact of coronavirus disease 2019 on the number of newly diagnosed cancer patients and examinations and surgeries performed for cancer in Japan: a nationwide study.
BMC Cancer. 2022;22:1303.
PubMed Abstract available

BODARD S, Lassalle L, Larousserie F, Guinebert S, et al
Performance of Sonoelastography for predicting malignancy in soft tissue.
BMC Cancer. 2022;22:1305.
PubMed Abstract available

VOUTILAINEN S, Heikkila P, Bartkova J, Nevanlinna H, et al
Markers associated with genomic instability, immunogenicity and immune therapy responsiveness in Metaplastic carcinoma of the breast: Expression of gammaH2AX, pRPA2, P53, PD-L1 and tumor infiltrating lymphocytes in 76 cases.
BMC Cancer. 2022;22:1298.
PubMed Abstract available

ZHU P, Liu G, Wang X, Lu J, et al
Transcription factor c-Jun modulates GLUT1 in glycolysis and breast cancer metastasis.
BMC Cancer. 2022;22:1283.
PubMed Abstract available

LI M, Zheng Y, Li X, Shen X, et al
ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer.
BMC Cancer. 2022;22:1280.
PubMed Abstract available

YOUSEFI H, Bahramy A, Zafari N, Delavar MR, et al
Notch signaling pathway: a comprehensive prognostic and gene expression profile analysis in breast cancer.
BMC Cancer. 2022;22:1282.
PubMed Abstract available

GORMAN LS, Ruane H, Woof VG, Southworth J, et al
The co-development of personalised 10-year breast cancer risk communications: a 'think-aloud' study.
BMC Cancer. 2022;22:1264.
PubMed Abstract available

XU D, Xu N, Sun L, Yang Z, et al
TG2 as a novel breast cancer prognostic marker promotes cell proliferation and glycolysis by activating the MEK/ERK/LDH pathway.
BMC Cancer. 2022;22:1267.
PubMed Abstract available

PAIK HJ, Kim SJ, Kim KS, Kim Y, et al
Characteristics and chronologically changing patterns of late-onset breast cancer in Korean women of age >/= 70 years: A hospital based-registry study.
BMC Cancer. 2022;22:1261.
PubMed Abstract available

DE LA CRUZ-MERINO L, Gion M, Cruz J, Alonso-Romero JL, et al
Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015-04 (PANGEA-Breast) study.
BMC Cancer. 2022;22:1258.
PubMed Abstract available

DRAGVOLL I, Bofin AM, Soiland H, Taraldsen G, et al
Predictors of adherence and the role of primary non-adherence in antihormonal treatment of breast cancer.
BMC Cancer. 2022;22:1247.
PubMed Abstract available

JIANG C, Xiu Y, Yu X, Qiao K, et al
Prognostic value of a modified systemic inflammation score in breast cancer patients who underwent neoadjuvant chemotherapy.
BMC Cancer. 2022;22:1249.
PubMed Abstract available

LIANG X, Chen X, Yang Z, Liao Y, et al
Early prediction of pathological complete response to neoadjuvant chemotherapy combining DCE-MRI and apparent diffusion coefficient values in breast Cancer.
BMC Cancer. 2022;22:1250.
PubMed Abstract available

November 2022

MENG X, Li W, Meng Z, Li Y, et al
EIF4A3-induced circBRWD3 promotes tumorigenesis of breast cancer through miR-142-3p_miR-142-5p/RAC1/PAK1 signaling.
BMC Cancer. 2022;22:1225.
PubMed Abstract available

URAS C, Cabioglu N, Tokat F, Er O, et al
Favorable locoregional control in clinically node-negative hormone-receptor positive breast cancer with low 21-gene recurrence scores: a single-institution study with 10-year follow-up.
BMC Cancer. 2022;22:1217.
PubMed Abstract available

FREITAS-JUNIOR R, de Oliveira VM, Frasson AL, Cavalcante FP, et al
Management of early-stage triple-negative breast cancer: recommendations of a panel of experts from the Brazilian Society of Mastology.
BMC Cancer. 2022;22:1201.
PubMed Abstract available

SAXTON JM, Pickering K, Wane S, Humphreys H, et al
Co-designed weight management intervention for women recovering from oestrogen-receptor positive breast cancer.
BMC Cancer. 2022;22:1202.
PubMed Abstract available

JM S, K P, S W, H C, et al
The experiences and perceptions of female breast cancer patients regarding weight management during and after treatment for oestrogen-receptor positive disease: a qualitative study.
BMC Cancer. 2022;22:1189.
PubMed Abstract available

MEYER D, Pastor-Villaescusa B, Michel S, Hauner H, et al
Associations between circulating obesity-related biomarkers and prognosis in female breast cancer survivors: a systematic review of observational data in women enrolled in lifestyle intervention trials.
BMC Cancer. 2022;22:1187.
PubMed Abstract available

KE L, Li S, Cui H
The prognostic role of tumor mutation burden on survival of breast cancer: a systematic review and meta-analysis.
BMC Cancer. 2022;22:1185.
PubMed Abstract available

LEE TH, Chang JH, Jang BS, Kim JS, et al
Protocol for the postoperative radiotherapy in N1 breast cancer patients (PORT-N1) trial, a prospective multicenter, randomized, controlled, non-inferiority trial of patients receiving breast-conserving surgery or mastectomy.
BMC Cancer. 2022;22:1179.
PubMed Abstract available

SHANG C, Chen Q, Zu F, Ren W, et al
Integrated analysis identified prognostic microRNAs in breast cancer.
BMC Cancer. 2022;22:1170.
PubMed Abstract available

XIONG J, Zuo W, Wu Y, Wang X, et al
Ultrasonography and clinicopathological features of breast cancer in predicting axillary lymph node metastases.
BMC Cancer. 2022;22:1155.
PubMed Abstract available

DITSATHAM C, Sripan P, Chaiwun B, Klunklin P, et al
Breast Cancer Subtypes in Northern Thailand and Barriers to satisfactory survival outcomes.
BMC Cancer. 2022;22:1147.
PubMed Abstract available

SHARMNI VISHNU K, Win TT, Aye SN, Basavaraj AK, et al
Combined atezolizumab and nab-paclitaxel in the treatment of triple negative breast cancer: a meta-analysis on their efficacy and safety.
BMC Cancer. 2022;22:1139.
PubMed Abstract available

XU T, Zhang SM, Wu HM, Wen XM, et al
Prognostic significance of prognostic nutritional index and systemic immune-inflammation index in patients after curative breast cancer resection: a retrospective cohort study.
BMC Cancer. 2022;22:1128.
PubMed Abstract available

LI Y, Chen L, Lv J, Chen X, et al
Clinical application of artificial neural network (ANN) modeling to predict BRCA1/2 germline deleterious variants in Chinese bilateral primary breast cancer patients.
BMC Cancer. 2022;22:1125.
PubMed Abstract available

ROGINSKI M, Sifaki-Pistolla D, Stomby A, Velivasaki G, et al
Paradoxes of breast cancer incidence and mortality in two corners of Europe.
BMC Cancer. 2022;22:1123.
PubMed Abstract available

DE ALMEIDA MARQUES BERNABE R, de Souza Vieira M, Felicio de Souza V, Gomes Fontana L, et al
Muscle strength is associated with fracture risk obtained by fracture risk assessment tool (FRAX) in women with breast cancer.
BMC Cancer. 2022;22:1115.
PubMed Abstract available

October 2022

DEUTSCHMANN C, Bartsch R, Singer CF, Gschwantler-Kaulich D, et al
Atezolizumab plus nab-paclitaxel for unresectable, locally advanced or metastatic breast cancer: real-world results from a single academic center in Austria.
BMC Cancer. 2022;22:1099.
PubMed Abstract available

YAN D, Ju X, Luo B, Guan F, et al
Tumour stroma ratio is a potential predictor for 5-year disease-free survival in breast cancer.
BMC Cancer. 2022;22:1082.
PubMed Abstract available

CHERIFI F, Da Silva A, Johnson A, Blanc-Fournier C, et al
HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer.
BMC Cancer. 2022;22:1081.
PubMed Abstract available

NABI-MEYBODI M, Sahebnasagh A, Hakimi Z, Shabani M, et al
Effects of topical timolol for the prevention of radiation-induced dermatitis in breast cancer: a pilot triple-blind, placebo-controlled trial.
BMC Cancer. 2022;22:1079.
PubMed Abstract available

HAYNES BM, Cunningham K, Shekhar MPV
RAD6 inhibition enhances paclitaxel sensitivity of triple negative breast cancer cells by aggravating mitotic spindle damage.
BMC Cancer. 2022;22:1073.
PubMed Abstract available

LIU L, Zhai W, Wang F, Yu L, et al
Using machine learning to identify gene interaction networks associated with breast cancer.
BMC Cancer. 2022;22:1070.
PubMed Abstract available

KORONKIEWICZ M, Kazimierczuk Z, Orzeszko A
Antitumor activity of the protein kinase inhibitor 1-(beta-D-2'-deoxyribofuranosyl)-4,5,6,7-tetrabromo- 1H-benzimidazole in breast cancer cell lines.
BMC Cancer. 2022;22:1069.
PubMed Abstract available

ISMAIL AL-KHALIL W, Al-Salhi L, Rijjal S, Aljamali M, et al
The frequencies of CYP2D6 alleles and their impact on clinical outcomes of adjuvant tamoxifen therapy in Syrian breast cancer patients.
BMC Cancer. 2022;22:1067.
PubMed Abstract available

DI BENEDETTO C, Oh J, Choudhery Z, Shi W, et al
NSMCE2, a novel super-enhancer-regulated gene, is linked to poor prognosis and therapy resistance in breast cancer.
BMC Cancer. 2022;22:1056.
PubMed Abstract available

HAWKINS R, McWilliams L, Ulph F, Evans DG, et al
Healthcare professionals' views following implementation of risk stratification into a national breast cancer screening programme.
BMC Cancer. 2022;22:1058.
PubMed Abstract available

ZHANG J, Dong D, Wei Q, Ren L, et al
CXCL10 serves as a potential serum biomarker complementing SCC-Ag for diagnosing cervical squamous cell carcinoma.
BMC Cancer. 2022;22:1052.
PubMed Abstract available

WONG CHONG E, Joncas FH, Seidah NG, Calon F, et al
Circulating levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancers.
BMC Cancer. 2022;22:1049.
PubMed Abstract available

LEICHSENRING J, Vladimirova V, Solbach C, Karn T, et al
EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy.
BMC Cancer. 2022;22:1040.
PubMed Abstract available

ZHANG L, She R, Zhu J, Lu J, et al
Novel lipometabolism biomarker for chemotherapy and immunotherapy response in breast cancer.
BMC Cancer. 2022;22:1030.
PubMed Abstract available

September 2022

MCNAMEE N, de la Fuente LR, Santos-Martinez MJ, O'Driscoll L, et al
Proteomics profiling identifies extracellular vesicles' cargo associated with tumour cell induced platelet aggregation.
BMC Cancer. 2022;22:1023.
PubMed Abstract available

PIEK MW, de Boer JP, van Duijnhoven F, van der Wal JE, et al
The co-occurrence of both breast- and differentiated thyroid cancer: incidence, association and clinical implications for daily practice.
BMC Cancer. 2022;22:1018.
PubMed Abstract available

JEON Y, Jo U, Hong J, Gong G, et al
Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancer.
BMC Cancer. 2022;22:1014.
PubMed Abstract available

FONSECA MM, Alhassan T, Nisha Y, Koszycki D, et al
Correction: Randomized trial of surveillance with abbreviated MRI in women with a personal history of breast cancer- impact on patient anxiety and cancer detection.
BMC Cancer. 2022;22:1009.
PubMed

LINDMAN H, Wiklund F, Andersen KK
Long-term treatment patterns and survival in metastatic breast cancer by intrinsic subtypes - an observational cohort study in Sweden.
BMC Cancer. 2022;22:1006.
PubMed Abstract available

GONG M, Liu X, Zhao X, Wang H, et al
A pyroptosis-related gene signature predicting survival and tumor immune microenvironment in breast cancer and validation.
BMC Cancer. 2022;22:1005.
PubMed Abstract available

ARTHUR EK, Menon U, Reese JB, Browning K, et al
Profiles of women's adjustment after cancer based on sexual and psychosocial wellbeing: results of a cluster analysis.
BMC Cancer. 2022;22:1003.
PubMed Abstract available

JIANG Y, Wang B, Li JK, Li SY, et al
Collagen fiber features and COL1A1: are they associated with elastic parameters in breast lesions, and can COL1A1 predict axillary lymph node metastasis?
BMC Cancer. 2022;22:1004.
PubMed Abstract available

FILLBRUNN M, Signorovitch J, Andre F, Wang I, et al
PIK3CA mutation status, progression and survival in advanced HR + /HER2- breast cancer: a meta-analysis of published clinical trials.
BMC Cancer. 2022;22:1002.
PubMed Abstract available

HAJJ A, Khoury R, Hachem R, Awad A, et al
Clinical and genetic factors associated with self-reported cognitive deficits in women with breast cancer: the "CAGE-Cog" study.
BMC Cancer. 2022;22:996.
PubMed Abstract available

MCCLELLAN B, Gries P, Harlow B, Tiziani S, et al
An IGF-1R-mTORC1-SRPK2 signaling Axis contributes to FASN regulation in breast cancer.
BMC Cancer. 2022;22:976.
PubMed Abstract available

AL SAAD S, Al Shenawi H, Almarabheh A, Al Shenawi N, et al
Is laterality in breast Cancer still worth studying? Local experience in Bahrain.
BMC Cancer. 2022;22:968.
PubMed Abstract available

ALLAHYARI A, Ehsanpour A, Ansarinejad N, Mehrzad V, et al
Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial.
BMC Cancer. 2022;22:960.
PubMed Abstract available

PEPE FF, Cazzaniga ME, Baroni S, Riva F, et al
Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 stu
BMC Cancer. 2022;22:956.
PubMed Abstract available

WANG Y, Lu R, Chen P, Cui R, et al
Promoter methylation of transient receptor potential melastatin-related 7 (TRPM7) predicts a better prognosis in patients with Luminal A breast cancers.
BMC Cancer. 2022;22:951.
PubMed Abstract available

JIANG Y, Mason M, Cho Y, Chittiprolu A, et al
Tolerance to oral anticancer agent treatment in older adults with cancer: a secondary analysis of data from electronic health records and a pilot study of patient-reported outcomes.
BMC Cancer. 2022;22:950.
PubMed Abstract available

August 2022

MAHMOOD D, Ahmad A, Sharif F, Arslan SA, et al
Clinical application of low-level laser therapy (Photo-biomodulation therapy) in the management of breast cancer-related lymphedema: a systematic review.
BMC Cancer. 2022;22:937.
PubMed Abstract available

WANG Q, Li B, Liu Z, Shang H, et al
Prediction model of axillary lymph node status using automated breast ultrasound (ABUS) and ki-67 status in early-stage breast cancer.
BMC Cancer. 2022;22:929.
PubMed Abstract available

XU H, Zhang H, Guo W, Zhong X, et al
Safety and efficacy profile of Trastuzumab deruxtecan in solid cancer: pooled reanalysis based on clinical trials.
BMC Cancer. 2022;22:923.
PubMed Abstract available

XU H, Qi Z, Zhao Q, Xue J, et al
Lentinan enhances the antitumor effects of Delta-like 1 via neutrophils.
BMC Cancer. 2022;22:918.
PubMed Abstract available

GETU MA, Chen C, Wang P, Kantelhardt EJ, et al
Quality of life and its influencing factors among breast cancer patients at Tikur Anbessa specialised hospital, Addis Ababa, Ethiopia.
BMC Cancer. 2022;22:897.
PubMed Abstract available

NSAFUL J, Dedey F, Nartey E, Labi J, et al
The impact of a breast cancer educational intervention in Ghanaian high schools.
BMC Cancer. 2022;22:893.
PubMed Abstract available

ZHANG K, Chen L, Zheng H, Zeng Y, et al
Cytokines secreted from adipose tissues mediate tumor proliferation and metastasis in triple negative breast cancer.
BMC Cancer. 2022;22:886.
PubMed Abstract available

FONTVIEILLE E, His M, Biessy C, Navionis AS, et al
Inflammatory biomarkers and risk of breast cancer among young women in Latin America: a case-control study.
BMC Cancer. 2022;22:877.
PubMed Abstract available

ALNOUMAS L, van den Driest L, Apczynski Z, Lannigan A, et al
Evaluation of the role of KPNA2 mutations in breast cancer prognosis using bioinformatics datasets.
BMC Cancer. 2022;22:874.
PubMed Abstract available

XU A, Chu X, Zhang S, Zheng J, et al
Development and validation of a clinicoradiomic nomogram to assess the HER2 status of patients with invasive ductal carcinoma.
BMC Cancer. 2022;22:872.
PubMed Abstract available

SHEN K, Yao L, Zhu J, Gu X, et al
Impact of adjuvant chemotherapy on T1N0M0 breast cancer patients: a propensity score matching study based on SEER database and external cohort.
BMC Cancer. 2022;22:863.
PubMed Abstract available

LI L, Li F, Hu X, Wu Z, et al
LAP3 contributes to IFN-gamma-induced arginine depletion and malignant transformation of bovine mammary epithelial cells.
BMC Cancer. 2022;22:864.
PubMed Abstract available

CUSTODIO IDD, Nunes FSM, Lima MTM, de Carvalho KP, et al
Serum 25-hydroxyvitamin D and cancer-related fatigue: associations and effects on depression, anxiety, functional capacity and health-related quality of Life in breast cancer survivors during adjuvant endocrine therapy.
BMC Cancer. 2022;22:860.
PubMed Abstract available

LIU PH, Wei JC, Wang YH, Yeh MH, et al
Female breast cancer incidence predisposing risk factors identification using nationwide big data: a matched nested case-control study in Taiwan.
BMC Cancer. 2022;22:849.
PubMed Abstract available

KWON YJ, Seo EB, Jeong AJ, Lee SH, et al
The acidic tumor microenvironment enhances PD-L1 expression via activation of STAT3 in MDA-MB-231 breast cancer cells.
BMC Cancer. 2022;22:852.
PubMed Abstract available

ZHANG Y, Wu H, Yu Z, Li L, et al
Germline variants profiling of BRCA1 and BRCA2 in Chinese Hakka breast and ovarian cancer patients.
BMC Cancer. 2022;22:842.
PubMed Abstract available

CHO B, Perez M, Jeffe DB, Kreuter MW, et al
Factors associated with initiation and continuation of endocrine therapy in women with hormone receptor-positive breast cancer.
BMC Cancer. 2022;22:837.
PubMed Abstract available

July 2022

LIU N, Yang DW, Wu YX, Xue WQ, et al
Burden, trends, and risk factors for breast cancer in China from 1990 to 2019 and its predictions until 2034: an up-to-date overview and comparison with those in Japan and South Korea.
BMC Cancer. 2022;22:826.
PubMed Abstract available

RO V, Jones T, Silverman T, McGuinness JE, et al
Patient, primary care provider, and stakeholder perspectives on mammography screening frequency: lessons learned from a qualitative study.
BMC Cancer. 2022;22:819.
PubMed Abstract available

BRAHIM SM, Zein EE, Bonnet C, Hamed CT, et al
Screening of BRCA1/2 variants in Mauritanian breast cancer patients.
BMC Cancer. 2022;22:802.
PubMed Abstract available

BHAKKAN-MAMBIR B, Deloumeaux J, Luce D
Geographical variations of cancer incidence in Guadeloupe, French West Indies.
BMC Cancer. 2022;22:783.
PubMed Abstract available

DOS SANTOS RLB, Pepe VLE, Osorio-de-Castro CGS
Public procurement of antineoplastic agents used for treating breast cancer in Brazil between 2013 and 2019.
BMC Cancer. 2022;22:769.
PubMed Abstract available

FONSECA MM, Alhassan T, Nisha Y, Koszycki D, et al
Randomized trial of surveillance with abbreviated MRI in women with a personal history of breast cancer- impact on patient anxiety and cancer detection.
BMC Cancer. 2022;22:774.
PubMed Abstract available

TOAMA W, Wiederin J, Shanley R, Jewett P, et al
Impact of pectoralis muscle loss on cardiac outcome and survival in Cancer patients who received anthracycline based chemotherapy: retrospective study.
BMC Cancer. 2022;22:763.
PubMed Abstract available

JIA L, Li G, Ma N, Zhang A, et al
Soluble POSTN is a novel biomarker complementing CA153 and CEA for breast cancer diagnosis and metastasis prediction.
BMC Cancer. 2022;22:760.
PubMed Abstract available

June 2022

KHAN MA, Zheng M, Fu J, Tania M, et al
Thymoquinone upregulates IL17RD in controlling the growth and metastasis of triple negative breast cancer cells in vitro.
BMC Cancer. 2022;22:707.
PubMed Abstract available

PATULEIA SIS, Moelans CB, Koopman J, van Steenhoven JEC, et al
Patient-centered research: how do women tolerate nipple fluid aspiration as a potential screening tool for breast cancer?
BMC Cancer. 2022;22:705.
PubMed Abstract available

BORDE J, Laitman Y, Blumcke B, Niederacher D, et al
Polygenic risk scores indicate extreme ages at onset of breast cancer in female BRCA1/2 pathogenic variant carriers.
BMC Cancer. 2022;22:706.
PubMed Abstract available

REIS J, Boavida J, Tran HT, Lyngra M, et al
Assessment of preoperative axillary nodal disease burden: breast MRI in locally advanced breast cancer before, during and after neoadjuvant endocrine therapy.
BMC Cancer. 2022;22:702.
PubMed Abstract available

HU K, Wang C, Luo C, Zheng H, et al
Neuroendocrine pathways and breast cancer progression: a pooled analysis of somatic mutations and gene expression from two large breast cancer cohorts.
BMC Cancer. 2022;22:680.
PubMed Abstract available

WOLF J, Kurz S, Rothe T, Serpa M, et al
Incidental irradiation of the regional lymph nodes during deep inspiration breath-hold radiation therapy in left-sided breast cancer patients: a dosimetric analysis.
BMC Cancer. 2022;22:682.
PubMed Abstract available

DUZENLI C, Chan EK, Bergman AM, Grahame S, et al
A novel carbon-fibre adjustable reusable accessory (CARA) for supine breast positioning to reduce toxicity in breast adjuvant radiotherapy: a study protocol for a multicentre phase III randomized controlled trial.
BMC Cancer. 2022;22:673.
PubMed Abstract available

DARBEHESHTI F, Kadkhoda S, Keshavarz-Fathi M, Razi S, et al
Investigation of BRCAness associated miRNA-gene axes in breast cancer: cell-free miR-182-5p as a potential expression signature of BRCAness.
BMC Cancer. 2022;22:668.
PubMed Abstract available

SEHOVIC E, Urru S, Chiorino G, Doebler P, et al
Meta-analysis of diagnostic cell-free circulating microRNAs for breast cancer detection.
BMC Cancer. 2022;22:634.
PubMed Abstract available

YELLAPU NK, Ly T, Sardiu ME, Pei D, et al
Synergistic anti-proliferative activity of JQ1 and GSK2801 in triple-negative breast cancer.
BMC Cancer. 2022;22:627.
PubMed Abstract available

OMARINI C, Piacentini F, Sperduti I, Cerma K, et al
T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis.
BMC Cancer. 2022;22:623.
PubMed Abstract available

LI XF, Fu WF, Zhang J, Song CG, et al
An iron metabolism and immune related gene signature for the prediction of clinical outcome and molecular characteristics of triple-negative breast cancer.
BMC Cancer. 2022;22:619.
PubMed Abstract available

WANG Y, Song W, Zhou S, Chang S, et al
The genomic and transcriptome characteristics of lung adenocarcinoma patients with previous breast cancer.
BMC Cancer. 2022;22:618.
PubMed Abstract available

LI X, An C, Zhang W
Is it sufficient to evaluate metastatic bone involvement in breast cancer using SPECT/CT? A new approach of SPECT/CT-guided targeted bone marrow biopsy.
BMC Cancer. 2022;22:614.
PubMed Abstract available

May 2022

AMORNSUPAK K, Thongchot S, Thinyakul C, Box C, et al
HMGB1 mediates invasion and PD-L1 expression through RAGE-PI3K/AKT signaling pathway in MDA-MB-231 breast cancer cells.
BMC Cancer. 2022;22:578.
PubMed Abstract available

TSENG CH
Pioglitazone and breast cancer risk in female patients with type 2 diabetes mellitus: a retrospective cohort analysis.
BMC Cancer. 2022;22:559.
PubMed Abstract available

BENTLEY JR, Yu X, Karmarkar AM, Downer B, et al
Feasibility and thematic analysis of narrative visualization materials with physical activity monitoring among breast cancer survivors.
BMC Cancer. 2022;22:553.
PubMed Abstract available

REN X, Song Y, Zhang Y, Wu H, et al
Prognostic significance of different molecular typing methods and immune status based on RNA sequencing in HR-positive and HER2-negative early-stage breast cancer.
BMC Cancer. 2022;22:548.
PubMed Abstract available

KOHLS M, Freisling H, Charvat H, Soerjomataram I, et al
Impact of cumulative body mass index and cardiometabolic diseases on survival among patients with colorectal and breast cancer: a multi-centre cohort study.
BMC Cancer. 2022;22:546.
PubMed Abstract available

SAYAN M, Eren MF, Kilic SS, Kotek A, et al
Utilization of radiation therapy and predictors of noncompliance among Syrian refugees in Turkey.
BMC Cancer. 2022;22:532.
PubMed Abstract available

ZENG X, Jiang S, Ruan S, Zhu L, et al
Cardiovascular risk factors and breast cancer incidence in a large middle-aged cohort study.
BMC Cancer. 2022;22:534.
PubMed Abstract available

ZHOU J, Sun X, Zhang X, Yang H, et al
miR-107 is involved in the regulation of NEDD9-mediated invasion and metastasis in breast cancer.
BMC Cancer. 2022;22:533.
PubMed Abstract available

NGUYEN VAN LONG F, Lardy-Cleaud A, Carene D, Rossoni C, et al
Low level of Fibrillarin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancer.
BMC Cancer. 2022;22:526.
PubMed Abstract available

ESER K, Onder AH, Sezer E, Cil T, et al
Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study.
BMC Cancer. 2022;22:516.
PubMed Abstract available

BROWN J, Scardo S, Method M, Schlauch D, et al
A real-world retrospective study of the use of Ki-67 testing and treatment patterns in patients with HR+, HER2- early breast cancer in the United States.
BMC Cancer. 2022;22:502.
PubMed Abstract available

ROUX A, Cholerton R, Sicsic J, Moumjid N, et al
Study protocol comparing the ethical, psychological and socio-economic impact of personalised breast cancer screening to that of standard screening in the "My Personal Breast Screening" (MyPeBS) randomised clinical trial.
BMC Cancer. 2022;22:507.
PubMed Abstract available

MITAL S, Nguyen HV
Cost-effectiveness of using artificial intelligence versus polygenic risk score to guide breast cancer screening.
BMC Cancer. 2022;22:501.
PubMed Abstract available

MCLAUGHLIN PMJ, Klar M, Zwimpfer TA, Dutilh G, et al
Maintenance Therapy with Aromatase Inhibitor in epithelial Ovarian Cancer (MATAO): study protocol of a randomized double-blinded placebo-controlled multi-center phase III Trial.
BMC Cancer. 2022;22:508.
PubMed Abstract available

DELRIEU L, Hamy AS, Coussy F, Kassara A, et al
Digital phenotyping in young breast cancer patients treated with neoadjuvant chemotherapy (the NeoFit Trial): protocol for a national, multicenter single-arm trial.
BMC Cancer. 2022;22:493.
PubMed Abstract available

April 2022

LI J, Li H, Guan L, Lu Y, et al
The value of preoperative sentinel lymph node contrast-enhanced ultrasound for breast cancer: a large, multicenter trial.
BMC Cancer. 2022;22:455.
PubMed Abstract available

LEE HJ, Choi CH
Characterization of SN38-resistant T47D breast cancer cell sublines overexpressing BCRP, MRP1, MRP2, MRP3, and MRP4.
BMC Cancer. 2022;22:446.
PubMed Abstract available

CHEN H, Luo H, Wang J, Li J, et al
Identification of a pyroptosis-related prognostic signature in breast cancer.
BMC Cancer. 2022;22:429.
PubMed Abstract available

WINTRAECKEN VM, Vulik S, de Wild S, Dirksen C, et al
A descriptive systematic review of the relationship between personality traits and quality of life of women with non-metastatic breast cancer.
BMC Cancer. 2022;22:426.
PubMed Abstract available

HE Y, Han SB, Liu Y, Zhang JJ, et al
Role of APOA1 in the resistance to platinum-based chemotherapy in squamous cervical cancer.
BMC Cancer. 2022;22:411.
PubMed Abstract available

LUNARDI M, Al-Habbaa A, Abdelshafy M, Davey MG, et al
Genetic and RNA-related molecular markers of trastuzumab-chemotherapy-associated cardiotoxicity in HER2 positive breast cancer: a systematic review.
BMC Cancer. 2022;22:396.
PubMed Abstract available

GONCALVES R, Mota BS, Sobreira-Lima B, Ricci MD, et al
The oncological safety of autologous fat grafting: a systematic review and meta-analysis.
BMC Cancer. 2022;22:391.
PubMed Abstract available

XIE Y, Gou Q, Zhang Y, Xie K, et al
Association between age at initial diagnosis and post-metastasis mortality among women with recurrent metastatic breast cancer in China.
BMC Cancer. 2022;22:385.
PubMed Abstract available

HOU C, Xu B, Hao Y, Yang D, et al
Development and validation of polygenic risk scores for prediction of breast cancer and breast cancer subtypes in Chinese women.
BMC Cancer. 2022;22:374.
PubMed Abstract available

ZERELLA MA, Zaffaroni M, Ronci G, Dicuonzo S, et al
Single fraction ablative preoperative radiation treatment for early-stage breast cancer: the CRYSTAL study - a phase I/II clinical trial protocol.
BMC Cancer. 2022;22:358.
PubMed Abstract available

REYNOLDS LM, Cavadino A, Chin S, Little Z, et al
The benefits and acceptability of virtual reality interventions for women with metastatic breast cancer in their homes; a pilot randomised trial.
BMC Cancer. 2022;22:360.
PubMed Abstract available

March 2022

ZHU GL, Xu C, Yang KB, Tang SQ, et al
Causal relationship between genetically predicted depression and cancer risk: a two-sample bi-directional mendelian randomization.
BMC Cancer. 2022;22:353.
PubMed Abstract available

SHEWELL LK, Day CJ, Kutasovic JR, Abrahams JL, et al
N-glycolylneuraminic acid serum biomarker levels are elevated in breast cancer patients at all stages of disease.
BMC Cancer. 2022;22:334.
PubMed Abstract available

AMITANI M, Oba T, Kiyosawa N, Morikawa H, et al
Skeletal muscle loss during neoadjuvant chemotherapy predicts poor prognosis in patients with breast cancer.
BMC Cancer. 2022;22:327.
PubMed Abstract available

MANOUCHEHRI E, Taghipour A, Ebadi A, Homaei Shandiz F, et al
Understanding breast cancer risk factors: is there any mismatch between laywomen perceptions and expert opinions.
BMC Cancer. 2022;22:309.
PubMed Abstract available

MARTEI YM, Dauda B, Vanderpuye V
Correction: Breast cancer screening in sub-Saharan Africa: a systematic review and ethical appraisal.
BMC Cancer. 2022;22:306.
PubMed

DEN DEKKER BM, Christenhusz A, van Dalen T, Jongen LM, et al
A multicenter prospective cohort study to evaluate feasibility of radio-frequency identification surgical guidance for nonpalpable breast lesions: design and rationale of the RFID Localizer 1 Trial.
BMC Cancer. 2022;22:305.
PubMed Abstract available

HAN B, Zhen F, Zheng XS, Hu J, et al
Systematic analysis of the expression and prognostic value of ITPR1 and correlation with tumor infiltrating immune cells in breast cancer.
BMC Cancer. 2022;22:297.
PubMed Abstract available

SADAQA D, Farraj A, Naseef H, Alsaid H, et al
Risk of developing depression among breast cancer patients in Palestine.
BMC Cancer. 2022;22:295.
PubMed Abstract available

CHAN KS, Cheung SM, Senn N, Husain E, et al
Peri-tumoural spatial distribution of lipid composition and tubule formation in breast cancer.
BMC Cancer. 2022;22:285.
PubMed Abstract available

BHARDWAJ A, Embury MD, Ju Z, Wang J, et al
Gene signature associated with resistance to fluvastatin chemoprevention for breast cancer.
BMC Cancer. 2022;22:282.
PubMed Abstract available

JUNG H, Lu M, Quan ML, Cheung WY, et al
New method for determining breast cancer recurrence-free survival using routinely collected real-world health data.
BMC Cancer. 2022;22:281.
PubMed Abstract available

DUAN F, Zhong M, Ma Y, Song C, et al
The efficacy of human epidermal growth factor receptor 2 (HER2) blockade switching mode in refractory patients with HER2-positive metastatic breast cancer: a phase II, multicenter, single-arm study (SYSUCC-005).
BMC Cancer. 2022;22:271.
PubMed Abstract available

WANG C, Zhou Y, Lin Y, Mao F, et al
Rationale and design of a phase II trial of pyrotinib in combination with nab-paclitaxel as adjuvant therapy for N0/N1mi, HER2 + early breast cancer (PHAEDRA).
BMC Cancer. 2022;22:269.
PubMed Abstract available

YE F, Bian L, Wen J, Yu P, et al
Additional capecitabine use in early-stage triple negative breast cancer patients receiving standard chemotherapy: a new era? A meta-analysis of randomized controlled trials.
BMC Cancer. 2022;22:261.
PubMed Abstract available

YANG PJ, Hou MF, Ou-Yang F, Tsai EM, et al
Association of early-onset breast cancer with body mass index, menarche, and menopause in Taiwan.
BMC Cancer. 2022;22:259.
PubMed Abstract available

YANG TO, Cairns BJ, Pirie K, Green J, et al
Body size in early life and the risk of postmenopausal breast cancer.
BMC Cancer. 2022;22:232.
PubMed Abstract available

CHEN YB, Bao HS, Hu TT, He Z, et al
Comparison of comfort and complications of Implantable Venous Access Port (IVAP) with ultrasound guided Internal Jugular Vein (IJV) and Axillary Vein/Subclavian Vein (AxV/SCV) puncture in breast cancer patients: a randomized controlled study.
BMC Cancer. 2022;22:248.
PubMed Abstract available

HORIMOTO Y, Ishizuka Y, Ueki Y, Higuchi T, et al
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients.
BMC Cancer. 2022;22:242.
PubMed Abstract available

LOMAN BR, Russart KLG, Grant CV, Lynch AJ, et al
Mammary tumors alter the fecal bacteriome and permit enteric bacterial translocation.
BMC Cancer. 2022;22:245.
PubMed Abstract available

TANG R, Deng JP, Zhang L, Zhang WW, et al
Prognostic significance of the skeletal muscle index and systemic inflammatory index in patients with lymph node-positive breast cancer after radical mastectomy.
BMC Cancer. 2022;22:234.
PubMed Abstract available

ZHANG X, Mu X, Huang O, Wang Z, et al
ZNF703 promotes triple-negative breast cancer cells through cell-cycle signaling and associated with poor prognosis.
BMC Cancer. 2022;22:226.
PubMed Abstract available

February 2022

PARK SY, Lim JW
Cognitive behavioral therapy for reducing fear of cancer recurrence (FCR) among breast cancer survivors: a systematic review of the literature.
BMC Cancer. 2022;22:217.
PubMed Abstract available

ELBIAD O, Laraqui A, El Boukhrissi F, Mounjid C, et al
Prevalence of specific and recurrent/founder pathogenic variants in BRCA genes in breast and ovarian cancer in North Africa.
BMC Cancer. 2022;22:208.
PubMed Abstract available

MARTEI YM, Dauda B, Vanderpuye V
Breast cancer screening in sub-Saharan Africa: a systematic review and ethical appraisal.
BMC Cancer. 2022;22:203.
PubMed Abstract available

SARKER R, Islam MS, Moonajilin MS, Rahman M, et al
Effectiveness of educational intervention on breast cancer knowledge and breast self-examination among female university students in Bangladesh: a pre-post quasi-experimental study.
BMC Cancer. 2022;22:199.
PubMed Abstract available

JUNG JG, Ahn SH, Lee S, Kim EK, et al
No axillary surgical treatment for lymph node-negative patients after ultra-sonography [NAUTILUS]: protocol of a prospective randomized clinical trial.
BMC Cancer. 2022;22:189.
PubMed Abstract available

CLOUD AS, Vargheese AM, Gunewardena S, Shimak RM, et al
Loss of REST in breast cancer promotes tumor progression through estrogen sensitization, MMP24 and CEMIP overexpression.
BMC Cancer. 2022;22:180.
PubMed Abstract available

AMBROSIO MR, Magli E, Caliendo G, Sparaco R, et al
Serotoninergic receptor ligands improve Tamoxifen effectiveness on breast cancer cells.
BMC Cancer. 2022;22:171.
PubMed Abstract available

GOTO W, Kashiwagi S, Kamei Y, Watanabe C, et al
Relationship between serum lipid levels and the immune microenvironment in breast cancer patients: a retrospective study.
BMC Cancer. 2022;22:167.
PubMed Abstract available

VITALE SR, Ruigrok-Ritstier K, Timmermans AM, Foekens R, et al
The prognostic and predictive value of ESR1 fusion gene transcripts in primary breast cancer.
BMC Cancer. 2022;22:165.
PubMed Abstract available

BRAHIMETAJ R, Willekens I, Massart A, Forsyth R, et al
Improved automated early detection of breast cancer based on high resolution 3D micro-CT microcalcification images.
BMC Cancer. 2022;22:162.
PubMed Abstract available

LIAO Q, Deng D, Xie Q, Gong X, et al
Clinical characteristics, pregnancy outcomes and ovarian function of pregnancy-associated breast cancer patients: a retrospective age-matched study.
BMC Cancer. 2022;22:152.
PubMed Abstract available

ANDREWS C, Childers TC, Wiseman KD, Lawhon V, et al
Facilitators and barriers to reducing chemotherapy for early-stage breast cancer: a qualitative analysis of interviews with patients and patient advocates.
BMC Cancer. 2022;22:141.
PubMed Abstract available

BU X, Jin C, Fan R, Cheng ASK, et al
Unmet needs of 1210 Chinese breast cancer survivors and associated factors: a multicentre cross-sectional study.
BMC Cancer. 2022;22:135.
PubMed Abstract available

HEINIG M, Heinze F, Schwarz S, Haug U, et al
Initial and ten-year treatment patterns among 11,000 breast cancer patients undergoing breast surgery-an analysis of German claims data.
BMC Cancer. 2022;22:130.
PubMed Abstract available

January 2022

GRAY LA, Hernandez Alava M, Wailoo AJ
Correction to: Mapping the EORTC QLQ-C30 to EQ-5D-3L in patients with breast cancer.
BMC Cancer. 2022;22:112.
PubMed

VAN EIJK M, Vermunt MAC, van Werkhoven E, Wilthagen EA, et al
The influence of docetaxel schedule on treatment tolerability and efficacy in patients with metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.
BMC Cancer. 2022;22:104.
PubMed Abstract available

ZHONG YM, Tong F, Shen J
Lympho-vascular invasion impacts the prognosis in breast-conserving surgery: a systematic review and meta-analysis.
BMC Cancer. 2022;22:102.
PubMed Abstract available

GANESAMOORTHY D, Robertson AJ, Chen W, Hall MB, et al
Whole genome deep sequencing analysis of cell-free DNA in samples with low tumour content.
BMC Cancer. 2022;22:85.
PubMed Abstract available

RAINEY L, van der Waal D, Donnelly LS, Southworth J, et al
Women's health behaviour change after receiving breast cancer risk estimates with tailored screening and prevention recommendations.
BMC Cancer. 2022;22:69.
PubMed Abstract available

SALAS M, Mordin M, Castro C, Islam Z, et al
Health-related quality of life in women with breast cancer: a review of measures.
BMC Cancer. 2022;22:66.
PubMed Abstract available

TAKAMIZAWA S, Shimoi T, Satomi-Tsushita N, Yazaki S, et al
Neutrophil-to-lymphocyte ratio as a prognostic factor for patients with metastatic or recurrent breast cancer treated using capecitabine: a retrospective study.
BMC Cancer. 2022;22:64.
PubMed Abstract available

ZHOU K, Ning F, Wang W, Li X, et al
The mediator role of resilience between psychological predictors and health-related quality of life in breast cancer survivors: a cross-sectional study.
BMC Cancer. 2022;22:57.
PubMed Abstract available

EKSTROM K, Crescitelli R, Petursson HI, Johansson J, et al
Characterization of surface markers on extracellular vesicles isolated from lymphatic exudate from patients with breast cancer.
BMC Cancer. 2022;22:50.
PubMed Abstract available

RAUTENBERG T, Hodgkinson B, Zerwes U, Downes M, et al
Meta-analysis of health state utility values measured by EuroQol 5-dimensions (EQ5D) questionnaire in Chinese women with breast cancer.
BMC Cancer. 2022;22:52.
PubMed Abstract available

VACHENC S, Gobbo J, Moujarrebe SE, Desmoulins I, et al
OncoSNIPE(R) Study Protocol, a study of molecular profiles associated with development of resistance in solid cancer patients.
BMC Cancer. 2022;22:41.
PubMed Abstract available

WANG S, Jiang H, Zheng C, Gu M, et al
Secretion of BMP-2 by tumor-associated macrophages (TAM) promotes microcalcifications in breast cancer.
BMC Cancer. 2022;22:34.
PubMed Abstract available

OZAKI Y, Aoyama Y, Masuda J, Inagaki L, et al
Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study.
BMC Cancer. 2022;22:36.
PubMed Abstract available

CHITAPANARUX I, Onchan W, Wongmaneerung P, Somwangprasert A, et al
Integration of breast cancer care in a middle-income country: learning from Suandok Breast Cancer Network (SBCN).
BMC Cancer. 2022;22:26.
PubMed Abstract available

LI L, Ai L, Jia L, Zhang L, et al
High score of LDH plus dNLR predicts poor survival in patients with HER2-positive advanced breast cancer treated with trastuzumab emtansine.
BMC Cancer. 2022;22:29.
PubMed Abstract available

NAKAMOTO S, Watanabe J, Ohtani S, Morita S, et al
Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: a multicenter retrospective study.
BMC Cancer. 2022;22:31.
PubMed Abstract available

BOUFERRAA Y, Haibe Y, Chedid A, Jabra E, et al
The impact of young age (< 40 years) on the outcome of a cohort of patients with primary non-metastatic breast cancer: analysis of 10-year survival of a prospective study.
BMC Cancer. 2022;22:27.
PubMed Abstract available

LEE YJ, Kim Y, Choi BB, Kim JR, et al
The blood level of thioredoxin 1 as a supporting biomarker in the detection of breast cancer.
BMC Cancer. 2022;22:12.
PubMed Abstract available

HAJJ A, Chamoun R, Salameh P, Khoury R, et al
Fatigue in breast cancer patients on chemotherapy: a cross-sectional study exploring clinical, biological, and genetic factors.
BMC Cancer. 2022;22:16.
PubMed Abstract available

ESPOSITO MV, Fosso B, Nunziato M, Casaburi G, et al
Microbiome composition indicate dysbiosis and lower richness in tumor breast tissues compared to healthy adjacent paired tissue, within the same women.
BMC Cancer. 2022;22:30.
PubMed Abstract available

LAI Z, Brosnan M, Sokol ES, Xie M, et al
Landscape of homologous recombination deficiencies in solid tumours: analyses of two independent genomic datasets.
BMC Cancer. 2022;22:13.
PubMed Abstract available

December 2021

BARTMANN C, Fischer LM, Hubner T, Muller-Reiter M, et al
The effects of the COVID-19 pandemic on psychological stress in breast cancer patients.
BMC Cancer. 2021;21:1356.
PubMed Abstract available

RADES D, Narvaez CA, Dziggel L, Janssen S, et al
A prospective interventional study investigating sleep disorders prior to and during adjuvant radiotherapy for breast cancer.
BMC Cancer. 2021;21:1349.
PubMed Abstract available

OLSEN M, Fischer K, Bossuyt PM, Goetghebeur E, et al
Evaluating the prognostic performance of a polygenic risk score for breast cancer risk stratification.
BMC Cancer. 2021;21:1351.
PubMed Abstract available

KARSONO R, Haryono SJ, Karsono B, Harahap WA, et al
ESR1 PvuII polymorphism: from risk factor to prognostic and predictive factor of the success of primary systemic therapy in advanced breast cancer.
BMC Cancer. 2021;21:1348.
PubMed Abstract available

RUFF GL, Murphy KE, Smith ZR, Vertino PM, et al
Subtype-Independent ANP32E Reduction During Breast Cancer Progression in Accordance with Chromatin Relaxation.
BMC Cancer. 2021;21:1342.
PubMed Abstract available

PARK HL, Chang J, Haridass V, Wang SS, et al
Mammography screening and mortality by risk status in the California teachers study.
BMC Cancer. 2021;21:1341.
PubMed Abstract available

ZHANG MK, Wang B, Li SY, Liu G, et al
TGF-beta1 and its signal molecules: are they correlated with the elasticity characteristics of breast lesions?
BMC Cancer. 2021;21:1336.
PubMed Abstract available

LIN S, Mo H, Li Y, Guan X, et al
Clinicopathological characteristics and survival outcomes in patients with synchronous lung metastases upon initial metastatic breast cancer diagnosis in Han population.
BMC Cancer. 2021;21:1330.
PubMed Abstract available

XU D, Zhang Y, Jin F
The role of AKR1 family in tamoxifen resistant invasive lobular breast cancer based on data mining.
BMC Cancer. 2021;21:1321.
PubMed Abstract available

LI F, Sun H, Li Y, Bai X, et al
High expression of eIF4E is associated with tumor macrophage infiltration and leads to poor prognosis in breast cancer.
BMC Cancer. 2021;21:1305.
PubMed Abstract available

ZHANG J, Jiang H, Zhang J, Bao G, et al
Effectiveness and safety of pegylated liposomal doxorubicin versus epirubicin as neoadjuvant or adjuvant chemotherapy for breast cancer: a real-world study.
BMC Cancer. 2021;21:1301.
PubMed Abstract available

GIACOMELLI C, Jung J, Wachter A, Ibing S, et al
Coordinated regulation of WNT/beta-catenin, c-Met, and integrin signalling pathways by miR-193b controls triple negative breast cancer metastatic traits.
BMC Cancer. 2021;21:1296.
PubMed Abstract available

KEPESIDIS KV, Bozic-Iven M, Huber M, Abdel-Aziz N, et al
Breast-cancer detection using blood-based infrared molecular fingerprints.
BMC Cancer. 2021;21:1287.
PubMed Abstract available

JIANG H, Meng L, Zhang H, Dai X, et al
Hypofractionated radiotherapy in ten fractions for postmastectomy patients: a phase II study compared with another hypofractionation schedule with sixteen fractions.
BMC Cancer. 2021;21:1284.
PubMed Abstract available

November 2021

MAZZONI AS, Brooke HL, Berntsen S, Nordin K, et al
Effect of self-regulatory behaviour change techniques and predictors of physical activity maintenance in cancer survivors: a 12-month follow-up of the Phys-Can RCT.
BMC Cancer. 2021;21:1272.
PubMed Abstract available

MASUDA N, Tamura K, Yasojima H, Shimomura A, et al
Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancer.
BMC Cancer. 2021;21:1269.
PubMed Abstract available

XIN Y, Shen G, Zheng Y, Guan Y, et al
Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer: a systematic review and meta-analysis.
BMC Cancer. 2021;21:1261.
PubMed Abstract available

KLEIN I, Kalichman L, Chen N, Susmallian S, et al
A comprehensive approach to risk factors for upper arm morbidities following breast cancer treatment: a prospective study.
BMC Cancer. 2021;21:1251.
PubMed Abstract available

SHI Y, Liu C
Circular RNA hsa_circ_0043278 inhibits breast cancer progression via the miR-455-3p/EI24 signalling pathway.
BMC Cancer. 2021;21:1249.
PubMed Abstract available

GRAY LA, Hernandez Alava M, Wailoo AJ
Mapping the EORTC QLQ-C30 to EQ-5D-3L in patients with breast cancer.
BMC Cancer. 2021;21:1237.
PubMed Abstract available

ZHENG G, Sundquist J, Sundquist K, Ji J, et al
Family history of breast cancer as a second primary malignancy in relatives: a nationwide cohort study.
BMC Cancer. 2021;21:1210.
PubMed Abstract available

CHOI SH, Yoon HS, Yoo SA, Yun SH, et al
Correction to: Co-relation with novel phosphorylation sites of IkappaBalpha and necroptosis in breast cancer cells.
BMC Cancer. 2021;21:1198.
PubMed

MIGEOTTE A, Dufour V, van Maanen A, Berliere M, et al
Impact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer.
BMC Cancer. 2021;21:1204.
PubMed Abstract available

WANG Z, Hu S, Li X, Liu Z, et al
MiR-16-5p suppresses breast cancer proliferation by targeting ANLN.
BMC Cancer. 2021;21:1188.
PubMed Abstract available

ZHAO XR, Fang H, Tang Y, Hu ZH, et al
POstmastectomy radioThErapy in Node-posiTive breast cancer with or without Internal mAmmary nodaL irradiation (POTENTIAL): a study protocol for a multicenter prospective phase III randomized controlled trial.
BMC Cancer. 2021;21:1185.
PubMed Abstract available

VAN PARIJS H, Vinh-Hung V, Fontaine C, Storme G, et al
Cardiopulmonary-related patient-reported outcomes in a randomized clinical trial of radiation therapy for breast cancer.
BMC Cancer. 2021;21:1177.
PubMed Abstract available

WIJERATNE DT, Gunasekera S, Booth CM, Promod H, et al
Demographic, tumour, and treatment characteristics of female patients with breast cancer in Sri Lanka; results from a hospital-based cancer registry.
BMC Cancer. 2021;21:1175.
PubMed Abstract available

XIE Y, Gong C, Zhang J, Wang L, et al
Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases.
BMC Cancer. 2021;21:1174.
PubMed Abstract available

October 2021

TONNEAU M, Mouttet-Audouard R, Le Tinier F, Mirabel X, et al
Stereotactic body radiotherapy for intramedullary metastases: a retrospective series at the Oscar Lambret center and a systematic review.
BMC Cancer. 2021;21:1168.
PubMed Abstract available

TANG W, Xu F, Zhao M, Zhang S, et al
Ferroptosis regulators, especially SQLE, play an important role in prognosis, progression and immune environment of breast cancer.
BMC Cancer. 2021;21:1160.
PubMed Abstract available

CREEDEN JF, Nanavaty NS, Einloth KR, Gillman CE, et al
Homologous recombination proficiency in ovarian and breast cancer patients.
BMC Cancer. 2021;21:1154.
PubMed Abstract available

SAJJADI E, Venetis K, Piciotti R, Gambini D, et al
Combined analysis of PTEN, HER2, and hormone receptors status: remodeling breast cancer risk profiling.
BMC Cancer. 2021;21:1152.
PubMed Abstract available

KIM K, Kim IJ, Pak K, Kang T, et al
Prognostic value of metabolic activity of the psoas muscle evaluated by preoperative (18)F-FDG PET-CT in breast cancer: a retrospective cross-sectional study.
BMC Cancer. 2021;21:1151.
PubMed Abstract available

AL RABADI LS, Cook MM, Kaempf AJ, Saraceni MM, et al
Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab.
BMC Cancer. 2021;21:1150.
PubMed Abstract available

SHIMOI T, Hashimoto J, Sudo K, Shimomura A, et al
Hotspot mutation profiles of AKT1 in Asian women with breast and endometrial cancers.
BMC Cancer. 2021;21:1131.
PubMed Abstract available

TAKADA K, Kashiwagi S, Asano Y, Goto W, et al
Clinical verification of body mass index and tumor immune response in patients with breast cancer receiving preoperative chemotherapy.
BMC Cancer. 2021;21:1129.
PubMed Abstract available

BERTOZZI S, Londero AP, Viola L, Orsaria M, et al
TFEB, SIRT1, CARM1, Beclin-1 expression and PITX2 methylation in breast cancer chemoresistance: a retrospective study.
BMC Cancer. 2021;21:1118.
PubMed Abstract available

MERINO T, Pinto MP, Orellana MP, Martinez G, et al
Multimodal assessment of acute cardiac toxicity induced by thoracic radiotherapy in cancer patients. Study protocol.
BMC Cancer. 2021;21:1114.
PubMed Abstract available

AHSBERG K, Gardfjell A, Nimeus E, Ryden L, et al
The PROCEM study protocol: Added value of preoperative contrast-enhanced mammography in staging of malignant breast lesions - a prospective randomized multicenter study.
BMC Cancer. 2021;21:1115.
PubMed Abstract available

HE Y, Tao Q, Zhou F, Si Y, et al
The relationship between dairy products intake and breast cancer incidence: a meta-analysis of observational studies.
BMC Cancer. 2021;21:1109.
PubMed Abstract available

KIRKHAM AA, King K, Joy AA, Pelletier AB, et al
Rationale and design of the Diet Restriction and Exercise-induced Adaptations in Metastatic breast cancer (DREAM) study: a 2-arm, parallel-group, phase II, randomized control trial of a short-term, calorie-restricted, and ketogenic diet plus exercise
BMC Cancer. 2021;21:1093.
PubMed Abstract available

TSUKAMOTO F, Arihiro K, Takahashi M, Ito KI, et al
Multicenter retrospective study on the use of Curebest 95GC Breast for estrogen receptor-positive and node-negative early breast cancer.
BMC Cancer. 2021;21:1077.
PubMed Abstract available

September 2021

LEE J, Jung JH, Kim WW, Kang B, et al
Short-term serial assessment of electronic patient-reported outcome for depression and anxiety in breast Cancer.
BMC Cancer. 2021;21:1065.
PubMed Abstract available

LIN Y, Zhou X, Peng W, Wu J, et al
Expression and clinical implications of basic leucine zipper ATF-like transcription factor 2 in breast cancer.
BMC Cancer. 2021;21:1062.
PubMed Abstract available

ABEBE E, Tollesa T, Assefa M, Tilahun Z, et al
Cognitive functioning and its associated factors among breast cancer patients on chemotherapy at Tikur Anbessa specialized hospital, Addis Ababa Ethiopia: an institution-based comparative cross-sectional study.
BMC Cancer. 2021;21:1052.
PubMed Abstract available

AKINYEMIJU T, Jones K, Gupta A, Oyekunle T, et al
Association of body composition with odds of breast cancer by molecular subtype: analysis of the Mechanisms for Established and Novel Risk Factors for Breast Cancer in Nigerian Women (MEND) study.
BMC Cancer. 2021;21:1051.
PubMed Abstract available

RODRIGUEZ-ACEVEDO AJ, Chan RJ, Olsen CM, Pandeya N, et al
Out-of-pocket medical expenses compared across five years for patients with one of five common cancers in Australia.
BMC Cancer. 2021;21:1055.
PubMed Abstract available

LIU J, Yin J, Liu Y, Xu Z, et al
Characteristics of 1270 Chinese sibling pairs with cancer.
BMC Cancer. 2021;21:1027.
PubMed Abstract available

DIMITROVA D, Naghavi B, Richter R, Nasser S, et al
Influence of migrant background on patient preference and expectations in breast and gynecological malignancies (NOGGO-expression V study): results of a prospective multicentre study in 606 patients in Germany.
BMC Cancer. 2021;21:1018.
PubMed Abstract available

AMAYA C, Luo S, Baigorri J, Baucells R, et al
Exposure to low intensity ultrasound removes paclitaxel cytotoxicity in breast and ovarian cancer cells.
BMC Cancer. 2021;21:981.
PubMed Abstract available

August 2021

TAVARES MC, Sampaio CD, Lima GE, Andrade VP, et al
A high CD8 to FOXP3 ratio in the tumor stroma and expression of PTEN in tumor cells are associated with improved survival in non-metastatic triple-negative breast carcinoma.
BMC Cancer. 2021;21:901.
PubMed Abstract available

July 2021

JIANG J, Chen J, Li W, Li Y, et al
Inter-observer variations of the tumor bed delineation for patients after breast conserving surgery in preoperative magnetic resonance and computed tomography scan fusion.
BMC Cancer. 2021;21:838.
PubMed Abstract available

LAMBERT P, Pitz M, Singh H, Decker K, et al
Evaluation of algorithms using administrative health and structured electronic medical record data to determine breast and colorectal cancer recurrence in a Canadian province : Using algorithms to determine breast and colorectal cancer recurrence.
BMC Cancer. 2021;21:763.
PubMed Abstract available

June 2021

YOO TK, Park SH, Do Han K, Chae BJ, et al
Cardiovascular events and mortality in a population-based cohort initially diagnosed with ductal carcinoma in situ.
BMC Cancer. 2021;21:735.
PubMed Abstract available

GUO L, Xie G, Wang R, Yang L, et al
Local treatment for triple-negative breast cancer patients undergoing chemotherapy: breast-conserving surgery or total mastectomy?
BMC Cancer. 2021;21:717.
PubMed Abstract available

BAKOS B, Kiss A, Arvai K, Szili B, et al
Co-occurrence of thyroid and breast cancer is associated with an increased oncogenic SNP burden.
BMC Cancer. 2021;21:706.
PubMed Abstract available

YU J, Lin C, Huang J, Hong J, et al
Efficacy of adjuvant chemotherapy stratified by age and the 21-gene recurrence score in estrogen receptor-positive breast cancer.
BMC Cancer. 2021;21:707.
PubMed Abstract available

DHAKA B, Sabarinathan R
Differential chromatin accessibility landscape of gain-of-function mutant p53 tumours.
BMC Cancer. 2021;21:669.
PubMed Abstract available

KOTNIK U, Peterlin B, Lovrecic L
Identification of women at risk for hereditary breast and ovarian cancer in a sample of 1000 Slovenian women: a comparison of guidelines.
BMC Cancer. 2021;21:665.
PubMed Abstract available

May 2021

ZHENG L, Zheng F, Xing Z, Zhang Y, et al
Breast lesions excised via vacuum-assisted system: could we get any clues for B3 lesions before excision biopsy?
BMC Cancer. 2021;21:633.
PubMed Abstract available

KOTANI H, Terada M, Mori M, Horisawa N, et al
Compression therapy using surgical gloves does not prevent paclitaxel-induced peripheral neuropathy: results from a double-blind phase 2 trial.
BMC Cancer. 2021;21:548.
PubMed Abstract available

YANG S, Bian J, George TJ, Daily K, et al
The association between cognitive impairment and breast and colorectal cancer screening utilization.
BMC Cancer. 2021;21:539.
PubMed Abstract available

ZHOU X, Zheng Z, Li Y, Zhao W, et al
The clinical features and prognosis of patients with mucinous breast carcinoma compared with those with infiltrating ductal carcinoma: a population-based study.
BMC Cancer. 2021;21:536.
PubMed Abstract available

YANG JR, Kuo WL, Yu CC, Chen SC, et al
Reconstructive outcome analysis of the impact of neoadjuvant chemotherapy on immediate breast reconstruction: a retrospective cross-sectional study.
BMC Cancer. 2021;21:522.
PubMed Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.